Clinical Trial

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with invasive fungal infection (IFI).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12-16 -> 2027-03-31 2026-08-13
minor Completion pushed: 2026-12-31 -> 2027-04-15 2026-08-13
Trial Details
NCT Number NCT04665037
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Invasive Fungal Infection
Enrollment 40 participants
Start Date 2022-02-22
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12